Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Free Report) – Brookline Capital Management issued their Q4 2025 earnings estimates for shares of Verrica Pharmaceuticals in a research note issued on Tuesday, March 11th. Brookline Capital Management analyst K. Dolliver anticipates that the company will earn ($0.03) per share for the quarter. The consensus estimate for Verrica Pharmaceuticals’ current full-year earnings is ($1.46) per share.
Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. The company had revenue of $0.34 million during the quarter, compared to the consensus estimate of $1.30 million.
Read Our Latest Stock Report on VRCA
Verrica Pharmaceuticals Price Performance
NASDAQ VRCA opened at $0.54 on Friday. Verrica Pharmaceuticals has a 12 month low of $0.54 and a 12 month high of $11.41. The company has a market cap of $24.50 million, a P/E ratio of -0.29 and a beta of 1.44. The company has a 50-day moving average of $0.67 and a 200-day moving average of $1.08.
Institutional Trading of Verrica Pharmaceuticals
A number of institutional investors have recently modified their holdings of the company. Invesco Ltd. purchased a new position in Verrica Pharmaceuticals in the 4th quarter worth approximately $32,000. Barclays PLC boosted its holdings in Verrica Pharmaceuticals by 404.6% in the 3rd quarter. Barclays PLC now owns 31,341 shares of the company’s stock worth $45,000 after acquiring an additional 25,130 shares during the period. Sanctuary Advisors LLC purchased a new position in Verrica Pharmaceuticals in the 3rd quarter worth approximately $87,000. Verition Fund Management LLC purchased a new position in Verrica Pharmaceuticals in the 3rd quarter worth approximately $89,000. Finally, Jane Street Group LLC boosted its holdings in Verrica Pharmaceuticals by 106.5% in the 3rd quarter. Jane Street Group LLC now owns 69,872 shares of the company’s stock worth $101,000 after acquiring an additional 36,028 shares during the period. Hedge funds and other institutional investors own 42.45% of the company’s stock.
Verrica Pharmaceuticals Company Profile
Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.
Further Reading
- Five stocks we like better than Verrica Pharmaceuticals
- Technology Stocks Explained: Here’s What to Know About Tech
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What is the Dow Jones Industrial Average (DJIA)?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How to Start Investing in Real Estate
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.